KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Castle Biosciences (CSTL) Accumulated Depreciation & Amortization (2018 - 2025)

Castle Biosciences' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $18.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 42.58% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $18.3 million, up 42.58%, while the annual FY2025 figure was $18.3 million, 42.58% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $18.3 million at Castle Biosciences, up from $16.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $18.3 million in Q4 2025 and bottomed at $867000.0 in Q2 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $7.3 million (2022), against an average of $7.9 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization soared 670.47% in 2022 before it skyrocketed 42.58% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.0 million in 2021, then skyrocketed by 138.53% to $7.3 million in 2022, then increased by 11.78% to $8.1 million in 2023, then surged by 58.22% to $12.8 million in 2024, then skyrocketed by 42.58% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Accumulated Depreciation & Amortization are $18.3 million (Q4 2025), $16.8 million (Q3 2025), and $12.8 million (Q4 2024).